Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Panels Favor Advair, Symbicort Over Single-Entity LABA Products For Asthma

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency must consider whether to change labeling, institute REMS or withdraw the indications for Serevent and Foradil, OND's Jenkins says.
Advertisement

Related Content

Clinical Trials Or Observational Studies For Asthma? FDA Advisory Panels Can't Agree
Clinical Trials Or Observational Studies For Asthma? FDA Advisory Panels Can't Agree
Clinical Trials Or Observational Studies for Asthma? FDA Advisory Panels Can't Agree
Clinical Trials Or Observational Studies for Asthma? FDA Advisory Panels Can't Agree
FDA Calls For Class-Wide REMS For LABA Asthma Drugs
FDA Calls For Class-Wide REMS For LABA Asthma Drugs
Asthma Trial Design To Be Focus Of Advisory Committee
Glaxo's Plan To Build On Its Respiratory Heritage Is Riding On Horizon Studies
GSK/Theravance Press On With LABA After Cmtes. Cut Asthma Indication
GSK/Theravance Press Forward With Once-Daily LABA After FDA Vote On Asthma Class

Topics

Advertisement
UsernamePublicRestriction

Register

PS067112

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel